Clinical Trials


Drug Interaction - Oral Contraceptive

This study has been completed
Bristol-Myers Squibb

Information provided by (Responsible Party)
Bristol-Myers Squibb Identifier

First received: November 14, 2006
Last updated: April 13, 2011
Last Verified: April 2011
History of Changes


The purpose of this study is to administer a combined oral contraceptive containing ethinyl estradiol and norgestimate with the HIV treatment of efavirenz to healthy females in order to assess if the concentrations of the oral contraceptives change. The safety of this treatment regimen will also be studied.

Condition Intervention Phase
HIV Infections

Drug : Ortho Tri-Cyclen LO
Drug : Ortho Cyclen
Drug : Ortho Cyclen + Efavirenz
Drug : Ortho Cyclen
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Study to Evaluate the Effect of Efavirenz Coadministration on the Pharmacokinetics of the Active Moieties of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures

  • To determine the effect coadministration of efavirenz 600 mg on the pharmacokinetics of ethinyl estradiol and the metabolite of norgestimate [ Time Frame: throughout the study ]
Secondary Outcome Measures:
  • Characterize the pharmacokinetics of efavirenz coadministered with the oral contraceptive Ortho Cyclen [ Time Frame: throughout the study ]
  • Assess the effect of efavirenz coadministered with Ortho Cyclen on serum progesterone levels [ Time Frame: throughout the study ]
  • Assess the safety of efavirenz coadministered with Ortho Cyclen [ Time Frame: throughout the study ]

Enrollment: 28
Study Start Date: December 2006
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: A

Drug: Ortho Tri-Cyclen LO

Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.

Active Comparator: B

Drug: Ortho Cyclen

Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.

Active Comparator: C

Drug: Ortho Cyclen + Efavirenz

Tablet, oral, OC + EFV 600 mg, once daily, 14 days.

Other Name: Sustiva
Active Comparator: D

Drug: Ortho Cyclen

Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.



Ages Eligible for Study: 18 Years to 45 Years  
Sexes Eligible for Study: Female  
Accepts Healthy Volunteers: Yes  


Inclusion Criteria:

  • Women of childbearing potential with intact ovarian function who have been on a stable method of oral contraceptives for at least 2 months prior to the start of the study.
  • Documented acceptable Pap smear within 1 year of the start of the study
  • BMI of 18-32 kg/m²

Exclusion Criteria:
  • Males
  • Subjects with abnormal menstrual cycle within 2 months prior to the start of the study
  • History of conditions in which oral contraceptives are contraindicated
  • History of migraine with focal aura
  • History of uncontrolled hypertension
  • Positive screening test for HIV-1,-2, HIV viral RNA, Hepatitis B surface antigen, or Hepatitis C antibody
  • History of diagnosed mental illness or suicidal ideation

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00399685


United States, California
Covance Clinical Research Unit San Diego
San Diego, California, United States, 92123
United States, Washington
Northwest Kinetics
Tacoma, Washington, United States, 98418

Sponsors and Collaborators

Bristol-Myers Squibb


Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
More Information

More Information

Responsible Party: Bristol-Myers Squibb Identifier: NCT00399685   History of Changes  
Other Study ID Numbers: AI266-145  
Study First Received: November 14, 2006  
Last Updated: April 13, 2011  

Keywords provided by Bristol-Myers Squibb:


Additional relevant MeSH terms:
HIV Infections
Norgestimate, ethinyl estradiol drug combination processed this data on June 01, 2020
This information is provided by